Drug discovery Archives

News and Trends 9 Feb 2023

Icosagen receives €18M loan for R&D and new facility

The Estonian biopharma company Icosagen AS has reached an €18 million financing agreement with the European Investment Bank (EIB) backed by the InvestEU program. The funds will strengthen the company’s drug discovery, development and production services. The funds are part of Icosagen’s €40 million investment into increasing its innovative contract research and development capabilities as […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Possible drug targets from Korean atherosclerosis research

Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

Opinion 1 Feb 2023

Computational chemistry and cancer

by Martin Slater, Cresset Discovery Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological testing to provide a complete and reliable picture of a target system. This is perhaps no better illustrated than in Cresset Discovery’s project with University of South Australia, which […]

February 1, 2023 - 3 minutesmins - By External Contributor

cancer cell screening drug discovery microplate

Cancer cell line screening: a compass for drug discovery

Large-panel cancer cell line screening can help find the right fit between a specific cancer cell and a therapeutic molecule, leading to the development of effective treatments. How can robust quality control, real-time screening methods, and a set of unique screening panels address current screening challenges? Human cell lines have been used in drug development […]

January 24, 2023 - 5 minutesmins - By Alexander Burik

Interview 19 Jan 2023

Interview: Proscia talks about digital pathology

Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has been a hot topic in drug discovery. Can you outline how it’s being applied to pathology data? Sure, it’s always great to start with such an exciting topic! There are two broad applications of AI that I want to highlight. […]

January 19, 2023 - 8 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design

A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source has been announced. The University of Oxford and Diamond Light Source already have many links but now intend to develop their collaborative work to address multiple […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

We DUB this target ‘druggable’

By Sheelagh Frame, CSO at Ubiquigent Modulation of the ubiquitin-proteasome system (UPS) presents a rich source for drug discovery. Recent years have seen the clinical validation of proteolysis-targeting chimeras (PROTACs) unlock the ability to drug the undruggable, by exploiting E3 ligases to mediate targeted protein degradation (TPD), paving the way to tackle exciting new drug […]

January 11, 2023 - 5 minutesmins - By External Contributor

News and Trends 20 Dec 2022

Watch: Interview with IRBM’s Heidi Kingdon Jones

The IRBM Group is an innovative research and discovery CRO (contract research organization) working across all aspects of drug discovery and early development. Headquartered in Italy, the company fosters collaborations with organizations from the pharma, biotech, non-profit and academic sectors to accelerate the development of vaccines and medicines. About 250 scientists work at the company’s […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 15 Dec 2022

Cyclica and SK Chemicals to co-develop novel therapeutics

Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

PrecisionLife to work on R&D with Ono Pharmaceutical

PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

PhoreMost and ThinkCyte collaborate on AI-based drug discovery

PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

cancer protein degradation sibylla biotech

Interview 14 Dec 2022

Sibylla Biotech: how physicists met biologists to discover new drugs

Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain how their interdisciplinary approach can speed up drug discovery in the protein degradation space. Protein degradation is a hot field in the biotech industry, with many pharmaceutical companies forging lucrative deals with protein degradation players. […]

December 14, 2022 - 9 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us